This market research report includes a detailed segmentation of the global respiratory drugs market by disease (asthma, COPD, allergic rhinitis, pulmonary hypertension, cystic fibrosis, and idiopathic pulmonary fibrosis). It also outlines the market shares for regions like the Americas, APAC, and Europe. The key vendors analyzed in this report are AstraZeneca, Boehringer, GSK, Merck, Roche, and Novartis.
The market research analysts at Technavio expect the global respiratory drugs market to grow at a CAGR of over 6% between 2016 and 2020. The increasing prevalence of respiratory diseases like asthma, COPD, allergic rhinitis, pulmonary hypertension, cystic fibrosis, and idiopathic pulmonary fibrosis will aid in the growth of this market during the forecast period. The increase in the usage of tobacco is also expected to impel the market for respiratory drugs worldwide during the predicted period. Currently, the Americas dominate the global respiratory drugs market, accounting for almost 56% of the overall market share. The introduction of new disease-modifying therapies is a key factor driving the market growth in this region.
The new market research report from Technavio presents a breakdown and analysis of the respiratory drugs segment by disease.
“Patience assistance programs are expected to play a crucial role in the growth of the global respiratory drugs market. Initiatives by vendors such as providing co-pay assistance to patients who are purchasing the indicated medications for respiratory diseases is projected to boost the sale of respiratory drugs across the globe. For instance, F. Hoffmann-La Roche’s drug Esbriet has a co-pay assistance program; according to which an eligible patient is required to pay $0 for a 12-month prescription, attaining a maximum benefit of $24,000 during the 12-month period,” says Barath Palada, Lead Analyst, Healthcare & Lifesciences, Technavio Research.
The global asthma drugs market is expected to cross $23 billion in revenue by 2020. The presence of the presence of late-stage pipeline molecules is expected to drive the market despite the loss of patent exclusivity of major drugs for this segment. Furthermore, the increased prevalence of asthma, use of combination drugs, in general, and the growing popularity of ICS/LABA combination drugs are some of the factors that are expected to propel the growth of the asthma drugs segment of the global respiratory drugs market during the forecast period.
The key vendors in the global respiratory drugs market include AstraZeneca, Boehringer, GSK, Merck, Roche, and Novartis. The global respiratory drugs market is highly competitive owing the presence of numerous small and large players that operate on a local or global scale. Companies that can manufacture and market effective respiratory drugs with high safety and efficacy profile are expected to gain a competitive edge over their rivals.
A more detailed analysis is available on the Technavio report, Global Respiratory Drugs Market 2016-2020.
We can customize reports by other regions and specific segments upon request.
Other related reports:
- Global Idiopathic Pulmonary Fibrosis Market 2016-2020
- Global Nebulizers Market 2016-2020
- Asthma Drugs Market in the US 2015-2019
- Global COPD and Asthma Devices Market – Industry Analysis 2015-2019
- Global Preventive Asthma Drugs Market 2015-2019
- Global Respiratory Disease Testing Market 2015-2019
- Global Respiratory Disease Testing Market 2015-2019
